Q-linea AB (publ) (STO:QLINEA)

Market Cap	330.84M
Revenue (ttm)	7.93M
Net Income (ttm)	-188.50M
Shares Out	6.44M
EPS (ttm)	-97.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,356
Average Volume	16,937
Open	50.80
Previous Close	51.40
Day's Range	50.80 - 53.00
52-Week Range	30.40 - 4,440.00
Beta	0.92
RSI	42.62
Earnings Date	Oct 29, 2025

About Q-linea AB

Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, European Union, the Middle East, and the United States. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture unit for incu...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2007
• Employees: 94
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: QLINEA

Financial Performance

In 2024, Q-linea AB's revenue was 4.14 million, a decrease of -25.21% compared to the previous year's 5.53 million. Losses were -216.87 million, -5.45% less than in 2023.